IRON — Disc Medicine Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $68.85
- 30-Day Move
- -25.2%
- Market Cap
- $2.5B
- Shares Outstanding
- 38,160,000
- P/B Ratio
- 4.25
- ROE
- -24.6%
Analyst consensus: Buy · 19 analysts
Disc Medicine Inc
A read-only Alphactor snapshot forDisc Medicine Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$68.85
30-Day Move
-25.2%
Market Cap
$2.5B
Shares Outstanding
38,160,000
P/B Ratio
4.25
ROE
-24.6%
$68.85
-25.2%last 90 delayed daily bars
90D High
$92.60
90D Low
$40.00
Avg Volume
653,198
IRON is down 25.2% over the last 30 trading days shown on this page.
Latest operating income is $-236M, which helps anchor the headline ratios with an actual earnings figure.
Dark Pool Short %
66.5%
Latest Close
$68.85
30-Day Move
-25.2%
Market Cap
$2.5B
Shares Outstanding
38,160,000
P/B Ratio
4.25
ROE
-24.6%
ROA
-22.0%
Debt / Equity
0.06
Current Ratio
21.48
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-236M
Net Income
$-212M
Gross Margin
--
Net Margin
--
Current Ratio
21.48
Debt / Equity
0.06
Altman Z
21.55
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.85x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-47M | $-47M | $-42M |
| 2023-12-31 | $0 | $-91M | $-76M | $-74M |
| 2024-12-31 | $0 | $-130M | $-109M | $-94M |
| 2025-12-31 | $0 | $-236M | $-212M | $-181M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$97M
Buys
0
Sells
70
Buy Value
$0
Sell Value
$97M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-14 | Franchi Jean M. | Sell | 6,257 | $69.24 |
| 2026-04-13 | Savage William Jacob | Sell | 2,200 | $66.81 |
| 2026-04-13 | Savage William Jacob | Sell | 3,531 | $66.12 |
| 2026-04-13 | Franchi Jean M. | Sell | 400 | $69.00 |
| 2026-03-02 | Savage William Jacob | Sell | 2,986 | $66.41 |
| 2026-03-02 | Savage William Jacob | Sell | 4,392 | $65.52 |
| 2026-02-25 | Franchi Jean M. | Sell | 353 | $69.06 |
| 2026-02-18 | Franchi Jean M. | Sell | 3,684 | $65.89 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1,656,623 | 0.04% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1,059,028 | 0.03% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 926,409 | 0.02% | 2025-12-31 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 650,000 | 0.02% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 604,856 | 0.02% | 2026-02-28 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 532,174 | 0.01% | 2026-02-28 |
| T. Rowe Price New Horizons Fund, Inc. | 471,851 | 0.01% | 2025-12-31 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 395,235 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
D.E. Shaw
Filed 2026-02-17
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$433M
+10.4%
Vanguard Group
Filed 2026-01-29
$140M
+22.1%
BlackRock
Filed 2024-08-13
$65M
--
Goldman Sachs
Filed 2026-02-10
$60M
+42.5%
Geode Capital Management
Filed 2026-02-09
$54M
+9.0%
4.32
Consensus
Buy—
—
—
19
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.